These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 11850897)

  • 1. Immunological approach in the diagnosis, therapy and prognosis of the exocrine pancreatic cancer.
    Bădulescu F; Bădulescu A; Rogoz S; Mustaţă R
    Roum Arch Microbiol Immunol; 2001; 60(1):5-16. PubMed ID: 11850897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer treatment: what's ahead?
    Parvez T
    J Coll Physicians Surg Pak; 2005 Nov; 15(11):738-45. PubMed ID: 16300718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological response modifier--immunotherapeutic approaches in pancreatic cancer.
    Schmiegel W
    Hepatogastroenterology; 1989 Dec; 36(6):456-8. PubMed ID: 2693301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcome of immunotherapy for patients with refractory pancreatic cancer.
    Nakamura M; Wada J; Suzuki H; Tanaka M; Katano M; Morisaki T
    Anticancer Res; 2009 Mar; 29(3):831-6. PubMed ID: 19414316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological response modifiers in cancer therapy.
    Gupta S; Kanodia AK
    Natl Med J India; 2002; 15(4):202-7. PubMed ID: 12296474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationales for combining chemotherapy and biotherapy in the treatment of cancer.
    Dillman RO
    Mol Biother; 1990 Dec; 2(4):201-7. PubMed ID: 2288719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The multidisciplinary management of gastrointestinal cancer. Pancreatic cancer: from pathogenesis to cure.
    Ducreux M; Boige V; Goéré D; Deutsch E; Ezra P; Elias D; Malka D
    Best Pract Res Clin Gastroenterol; 2007; 21(6):997-1014. PubMed ID: 18070700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Serum tumor markers at exocrine adenocarcinoma of pancreas].
    Holubec L; Finek J; Topolcan O; Svobodová S
    Cas Lek Cesk; 2005; 144(2):86-8; discussion 89. PubMed ID: 15807292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypoxic abdominal stop-flow perfusion in the treatment of advanced pancreatic cancer: a phase II evaluation/trial.
    Guadagni S; Clementi M; Valenti M; Fiorentini G; Cantore M; Kanavos E; Caterino GP; Di Giuro G; Amicucci G
    Eur J Surg Oncol; 2007 Feb; 33(1):72-8. PubMed ID: 17166688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological response modifiers: current use and future prospects in cancer therapy.
    Bisht M; Bist SS; Dhasmana DC
    Indian J Cancer; 2010; 47(4):443-51. PubMed ID: 21131760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in treatment for pancreatic cancer.
    Matsuno S; Egawa S; Arai K
    J Hepatobiliary Pancreat Surg; 2001; 8(6):544-8. PubMed ID: 11956906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Results of surgical treatment in ampullary and pancreatic carcinoma and its prognostic parameters after R0-resection].
    Ridwelski K; Meyer F; Schmidt U; Lippert H
    Zentralbl Chir; 2005 Aug; 130(4):353-61. PubMed ID: 16103961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunodominant PstS1 antigen of mycobacterium tuberculosis is a potent biological response modifier for the treatment of bladder cancer.
    Sänger C; Busche A; Bentien G; Spallek R; Jonas F; Böhle A; Singh M; Brandau S
    BMC Cancer; 2004 Nov; 4():86. PubMed ID: 15566565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Surgical therapy of locally advanced and primary inoperable pancreatic carcinoma after neoadjuvant preoperative radiochemotherapy].
    Rau HG; Wichmann MW; Wilkowski R; Heinemann V; Sackmann M; Helmberger T; Dühmke E; Schildberg FW
    Chirurg; 2002 Feb; 73(2):132-7. PubMed ID: 11974476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pancreatic head carcinoma: clinical analysis of 189 cases.
    Hua YP; Liang LJ; Peng BG; Li SQ; Huang JF
    Hepatobiliary Pancreat Dis Int; 2009 Feb; 8(1):79-84. PubMed ID: 19208521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting.
    Gray A; Raff AB; Chiriva-Internati M; Chen SY; Kast WM
    Immunol Rev; 2008 Apr; 222():316-27. PubMed ID: 18364011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy for pancreatic cancer - science driving clinical progress.
    Laheru D; Jaffee EM
    Nat Rev Cancer; 2005 Jun; 5(6):459-67. PubMed ID: 15905855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Translation of recent advances and discoveries in molecular biology and immunology in the diagnosis and treatment of pancreatic cancer.
    Albo D; Farrow B; Berger DH
    Surg Oncol Clin N Am; 2008 Apr; 17(2):357-76, ix. PubMed ID: 18375357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.